Precision Targeting Of Every Patient’s Medical “Moment Of Truth”

  • White paper

Summary

In a rapidly evolving medical landscape, the pharmaceutical industry is poised to revolutionize patient care with AI-based technology. These innovative tools have the potential to precisely diagnose and treat patients at critical junctures in their healthcare journey, often termed their "medical moment of truth." The extent to which companies can harness this technology will significantly dictate their success in the modern healthcare paradigm.

A vivid illustration of this transformative trend is Viz.ai, a leading player in the realm of AI-driven medical solutions. "In Vivo" sat down with the co-founder and CEO of Viz.ai, Chris Mansi, to shed light on the company's ambitions and its trajectory. With a multicultural background and a distinguished career that led him from Cambridge University to neurosurgery, Mansi's personal experiences underscored the urgency of bridging the gap in timely patient care. His encounters with delayed diagnoses, such as a young woman's head trauma that took hours to correctly diagnose, catalyzed his journey into AI and healthcare technology.

Viz.ai's groundbreaking platform is a testament to Mansi's vision. Offering real-time AI-powered stroke detection, the system is a beacon of hope for patients in need of immediate care. Operational round the clock, it equips clinicians with the tools to make swifter and more accurate decisions, dramatically enhancing patient outcomes. But Viz.ai isn't solely about technology; it embeds its ethos in a robust customer-centric approach. By positioning customer relations personnel directly on-site, the company ensures that its platform integrates seamlessly into medical workflows, fostering high levels of user engagement.

Peering into the future, Mansi envisions a medical world transformed by AI. He predicts a rise in hyper-specialization, where nuanced understandings of diseases, facilitated by AI, will allow for more personalized treatments. This technological democratization means that even a patient in a remote location could benefit from expert decisions made at globally renowned medical institutions. As AI continues to reshape the medical landscape, companies like Viz.ai stand at the forefront of this revolution, heralding a new era of enhanced patient care.


Name

Precision Targeting Of Every Patient’s Medical “Moment Of Truth”

Description

Read this interview with Dr. Chris Mansi, CEO of Viz.ai, on how the company's AI software is becoming a standardsetter for broader patient engagement with big pharma from advancing clinical trials to launching the next generation of specialty medicines.

Organization

Tech product

Referenced by